Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically…
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at…
MORRISTOWN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug…
AMSTERDAM, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology…
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing…
Survey results indicate that most organizations are planning to invest in AI within the next 1-3 years and are expecting AI…
Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and…
University of California selects AI purchasing platform to accelerate scientific and research procurement for 10 campusesOAKLAND, Calif., Sept. 12, 2024…
Starting price of $149 offers improved accessibility compared to market prices of brand-name medications which can be 8x higher.Noom stands…
New data published in JACC: Heart Failure demonstrate durable benefits in MLWHF and EQ-5D quality of life measures in heart…